Marksans Pharma (MARKSANS) | Stock Overview & Key Data
Marksans Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹210.00
High: ₹217.49
on August 8, 2025
52 Week Range
Low: ₹171.00
High: ₹358.70
on April 7, 2025
on December 2, 2024
All-Time High: ₹358.70 on December 2, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR102.3B
EPS
8.46
P/E Ratio (TTM)
26.68
Forward P/E
15.91
P/B Ratio
4.15
PEG Ratio
N/A
Div. Yield
0.62%
ROE
16.73%
Beta
1.262
Debt to Equity
12.93
Financial Highlights
Profitability
Gross Margin
54.09%
Operating Margin
14.54%
Profit Margin
14.51%
Returns and Earnings
Return on Assets (TTM)
9.40%
Return on Equity (TTM)
16.73%
EBITDA
INR6.0B
Net Income (TTM)
INR3.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR57.88
Quarterly Revenue Growth (YoY)
26.50%
Quarterly Earnings Growth (YoY)
15.70%
Dividend Information
Last 12-Month Dividend
₹1.40
Current Dividend Yield
0.62%
3-Year Average Dividend Yield
0.40%
3-Year Average Annual Dividend
₹0.72
3-Year Total Dividends
₹2.15
Ex-Dividend Date
August 1, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Marksans Pharma MARKSANS | 102.29B Mid-cap | -5.76% | -16.72% | -4.96% | -21.46% | -29.64% | 10.63% | 332.80% | 340.76% |
| GlaxoSmithKline GLAXO | 479.22B Large-cap | -15.34% | -18.49% | -6.07% | 21.26% | 19.95% | -6.38% | 85.69% | 76.49% |
| Pfizer PFIZER | 232.88B Large-cap | -3.36% | -13.98% | 17.41% | 15.19% | -5.42% | -13.67% | 19.64% | 12.63% |
| Sanofi India Limited SANOFI | 123.27B Mid-cap | -11.08% | -13.70% | -10.84% | -5.34% | -14.91% | -19.20% | -16.37% | -35.89% |
| Sanofi Consumer SANOFICONR | 122.41B Mid-cap | 5.55% | -3.59% | 4.57% | 10.16% | 5.54% | 9.44% | 9.44% | 9.44% |
| Senores SENORES | 31.62B Small-cap | -3.10% | 16.33% | 34.83% | 13.40% | 16.85% | 12.90% | 12.90% | 12.90% |
Ownership & Short Interest
Insider Ownership
46.37%
Institutional Ownership
17.23%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
2M
Average 90-Day Volume
1M
Marksans Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Marksans Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MARKSANS's 52-week high and low?
- In the last 52 weeks, Marksans Pharma reached a high of ₹358.70 (on December 2, 2024) and a low of ₹171.00 (on April 7, 2025).
- What is the market cap and P/E ratio for MARKSANS?
- Curious about Marksans Pharma's size and valuation? Its market capitalization stands at 102.29B. When it comes to valuation, the P/E ratio (trailing twelve months) is 26.68, and the forward P/E (looking ahead) is 15.91.
- Does MARKSANS pay dividends? If so, what's the yield?
- Yes, Marksans Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.62%, and the company has paid an average of ₹0.72 per share annually over the past 3 years.
- Who are Marksans Pharma's main competitors or similar companies to consider before investing?
When looking at Marksans Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return GlaxoSmithKline
GLAXO479.22B Healthcare Drug Manufacturers - General -6.38% 85.69% Pfizer
PFIZER232.88B Healthcare Drug Manufacturers - General -13.67% 19.64% Sanofi India Limited
SANOFI123.27B Healthcare Drug Manufacturers - General -19.20% -16.37% Sanofi Consumer
SANOFICONR122.41B Healthcare Drug Manufacturers - General 9.44% 9.44% Senores
SENORES31.62B Healthcare Drug Manufacturers - General 12.90% 12.90% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Marksans Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Marksans Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 16.73%, the Debt to Equity ratio from the most recent quarter is 12.93, and its Gross Profit Margin stands at 54.09%.
- What is the recent revenue and earnings growth for MARKSANS?
- Looking at Marksans Pharma's growth, its revenue over the trailing twelve months (TTM) was INR26B. Compared to the same quarter last year (YoY), quarterly revenue grew by 26.50%, and quarterly earnings saw a YoY growth of 15.70%.
- How much of MARKSANS stock is held by insiders and institutions?
- Wondering who owns Marksans Pharma stock? Company insiders (like executives and directors) hold about 46.37% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 17.23%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.